1.	Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 2003-1027, NCT00113334
2.	Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: M02-534, NCT00061659
3.	Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: M02-457, NCT00061672
4.	Phase II Randomized Study of ABT-510 in Patients With Locally Recurrent or Metastatic Renal Cell Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0308112, ABBOTT-M02-428, NCT00080704
5.	ABT-510 in Treating Patients With Metastatic Melanoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000582475, P30CA015083, MC0375, 1439-04, MAYO-MC0375, NCT00602199
6.	ABT-510 and Bevacizumab in Treating Patients With Advanced Solid Tumors Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000449951, DUMC-6074-05-7R1ER, DUMC-6074, NCT00276562